Prof. Tay Sun Kuie
Senior Consultant Obstetrician and Gynecologist
Singapore General Hospital
Optimizing triage of HPV positive patients with p16/Ki67 dual stain biomarkers: Singapore experience
The goal of cervical cancer screening is to detect precancerous lesions, which if left untreated, can develop into cervical cancer. While Pap cytology has had a positive impact on HPV and cervical cancer screening over the past 50 years, it is resource-intensive and subject to misinterpretation and missed disease.
By harnessing p16-Ki67 dual-biomarker immunocytochemistry, FDA-approved CINtec® PLUS Cytology serves as an objective indicator of transforming HPV infections in patients with abnormal Pap cytology and/or HPV-positive screening results.
In this webinar, our experts unveil how p16-Ki67 dual biomarker testing optimizes triage processes and allows lab professionals to help clinicians be more certain in selecting women who may benefit most from colposcopy and in follow up recommendations.
Join us in this session, as they share their experience with CINtec® PLUS biomarker testing, as a triage tool in managing patients with abnormal Pap and/or HPV-positive results.